{"filing":{"accession_number":"0001193125-26-388010","cik":"0001422142","ticker":"WHWK","company_name":"Whitehawk Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-09","primary_document":"d160342d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/d160342d8k.htm"},"events":[{"id":32730,"run_id":30092,"accession_number":"0001193125-26-388010","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Vijay Iyengar, M.D. to the Board of Directors of Whitehawk Therapeutics, effective September 9, 2026, as a Class III director. While the disclosure also includes compensatory details (stock option grant of 76,080 shares and base annual retainer of $40,000), the principal action is the appointment itself. Dr. Iyengar's extensive oncology and corporate strategy background from Incyte and Novartis makes this a material governance event affecting the composition of the board.","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35976,"accession_number":"0001193125-26-388010","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Vijay Iyengar, M.D. to the Board of Directors of Whitehawk Therapeutics, effective September 9, 2026, as a Class III director. While the disclosure also includes compensatory details (stock option grant of 76,080 shares and base annual retainer of $40,000), the principal action is the appointment itself. Dr. Iyengar's extensive oncology and corporate strategy background from Incyte and Novartis makes this a material governance event affecting the composition of the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T21:03:38.092329+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35976,"accession_number":"0001193125-26-388010","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Vijay Iyengar, M.D. to the Board of Directors of Whitehawk Therapeutics, effective September 9, 2026, as a Class III director. While the disclosure also includes compensatory details (stock option grant of 76,080 shares and base annual retainer of $40,000), the principal action is the appointment itself. Dr. Iyengar's extensive oncology and corporate strategy background from Incyte and Novartis makes this a material governance event affecting the composition of the board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T21:03:38.092329+00:00","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-09-10"}]}